ArticleUltrasound in medicine & biology2026
Local Delivery of miR-27a* Using Ultrasound-Targeted Microbubble Cavitation Inhibits Squamous Cell Carcinoma Growth.
Article in Ultrasound in medicine & biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveUltrasound-targeted microbubble (MB) cavitation (UTMC) is an image-guided therapeutic oligonucleotide delivery platform utilizing intravenously injected gas-filled ultrasound contrast agents, which carry the therapeutic on the MB shell. During transit of MBs in the microcirculation of target tissue, ultrasound causes MB oscillation, facilitating endocytosis-independent payload uptake within insonified cells. Here, we tested the hypothesis that UTMC-mediated miR-27a* delivery will reduce tumor growth rate and result in accumulation of miR-27a* within tumor cells and the tumor microenvironment.
methodsWe used UTMC to deliver miR-27a* to SCC-VII cells in vitro and in SCC-VII mouse tumor models. Pulsed ultrasound was delivered during intravenous (i.v.) infusion of lipid encapsulated MBs loading either miR-27a* (miR-27a*-MB + UTMC) or negative control MBs (Con-miR-MB + UTMC).
resultsmiR-27a*-MB+UTMC treatment significantly reduced SCC-VII cell viability in vitro and SCC-VII tumor growth in vivo compared to negative controls (Con-miR-MB+UTMC, i.v. miR-27a* or no treatment). Forty-eight hours following treatment, protein expression of direct miR-27a* targets (epidermal growth factor receptor [EGFR], NUP62 and ΔNP63α) was significantly reduced in miR-27a*-MB + UTMC vs i.v. miR-27a* or Con-miR-MB + UTMC. Further, whereas i.v. miR-27a* did not decrease tumor expression of these proteins vs. non-treated tumors, miR-27a*-MB + UTMC significantly reduced tumor expression of EGFR, NUP62 and ΔNP63α by 50%-75%, compared to non-treated tumors.
conclusionThese data substantiate the utility of UTMC for non-invasive delivery of oligonucleotide payloads to extravascular target sites and suggests the therapeutic potential of miR-27a* for the treatment of head and neck squamous cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.